| IPH Stock | | | EUR 1.60 0.09 5.33% |
President
Mr. Yannis Morel, Ph.D., was Executive Vice President Products Portfolio Strategy Business Development and Member of the Executive Board of Innate Pharma S.A. since June 23, 2017. He was Executive Vice President Business Development and Member of the Executive Board at the Company from December 12, 2015. Prior to that, he served as Executive Vice President and Chief Business Officer and Member of the Executive Committee of the Company from 2011. He joined the Company in December 2001. From 2001 to 2007, he held a number of positions in Research and Development at the Company, from Immunology Researcher to Team Leader and then Head of Research and Development Programs. He was in charge of business development at the Company since 2007 since 2017.
| Age | 50 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Phone | 33 4 30 30 30 30 |
| Web | https://www.innate-pharma.com |
Morel holds a Doctorate in oncology from Universite AixMarseille and is also a graduate of Ecole Normale Superieure de Cachan with a BS in physical and molecular chemistry.
Innate Pharma Management Efficiency
The company has return on total asset
(ROA) of
(0.043) % which means that it has lost $0.043 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.1731) %, meaning that it generated substantial loss on money invested by shareholders. Innate Pharma's management efficiency ratios could be used to measure how well Innate Pharma manages its routine affairs as well as how well it operates its assets and liabilities.
Innate Pharma has accumulated 46.5
M in total debt with debt to equity ratio
(D/E) of 2.7, implying the company greatly
relies on financing operations through barrowing. Innate Pharma has a current ratio of 1.59, which is within standard range for the sector. Debt can assist Innate Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Innate Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Innate Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Innate to invest in growth at high rates of return. When we think about Innate Pharma's use of debt, we should always consider it together with cash and equity.
Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. The company was founded in 1999 and is based in Marseille, France. INNATE PHARMA operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 191 people. Innate Pharma (IPH) is traded on Euronext Paris in France and employs 213 people.
Management Performance
Innate Pharma Leadership Team
Elected by the shareholders, the Innate Pharma's board of directors comprises two types of representatives: Innate Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Innate. The board's role is to monitor Innate Pharma's management team and ensure that shareholders' interests are well served. Innate Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Innate Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| DVM MBA, VP Founder | |
| Frederic MBA, VP CFO | |
| Odile Belzunce, VP Operations | |
| Mondher MD, Chairman CEO | |
| Herve Brailly, Chairman of the Management Board, Member of the Executive Committee, CEO | |
| Alessandro MD, Founder | |
| Jean Fourni, Founder | |
| Marc Bonneville, Founder | |
| Yannis Morel, Member of the Executive Committee, Executive Vice President Business Development | |
| Franois Romagn, Founder | |
Innate Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Innate Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Information and Resources on Investing in Innate Stock
When determining whether Innate Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innate Pharma's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innate Pharma Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Innate Pharma Stock: Check out
Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
For information on how to trade Innate Stock refer to our
How to Trade Innate Stock guide.
You can also try the
Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.